Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-03-03 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于召开2020年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2020 first extraordinary general meeting (临时股东大会) of Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, voting methods (onsite and online), agenda items for shareholder approval, registration procedures, and attachments such as proxy forms and voting instructions. The content focuses on informing shareholders about the meeting logistics and proposals to be voted on, including non-public stock issuance plans and shareholder return plans. There are no financial statements, audit opinions, or earnings data presented. The document is not a report itself but a formal announcement and invitation to a shareholder meeting with voting details. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the solicitation materials or the actual voting results, it is best classified as Proxy Solicitation & Information Statement (PSI).
2020-03-03 Chinese
关于非公开发行股票摊薄即期回报及填补措施的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement by 贝达药业股份有限公司 regarding a non-public issuance of shares, including analysis of the dilution impact on immediate returns, assumptions, financial impact projections, risk disclosures, and measures to mitigate dilution effects. It discusses the capital raising, use of proceeds, and related corporate governance and management commitments. The content focuses on capital structure changes and financing activities rather than a full annual or interim financial report. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. The document fits the description of a Capital/Financing Update (CAP) as it provides detailed information on the company's fundraising and capital structure changes through a non-public stock issuance and related impact analysis.
2020-03-03 Chinese
关于公司部分高级管理人员职务变动的公告
Board/Management Information Classification · 100% confidence The document is an announcement from a company about changes in senior management positions, including appointments and role adjustments of several executives. It includes detailed biographies and compliance statements for the appointed individuals. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2020-03-03 Chinese
前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "专项报告" (special report) on the usage of previously raised funds by the company 贝达药业股份有限公司, with detailed information on the amount raised, storage, usage, investment projects, changes, and economic benefits up to September 30, 2019. It references regulatory requirements from the China Securities Regulatory Commission and includes detailed financial figures and project descriptions related to the use of fundraising proceeds. The content focuses on the actual use of previously raised capital, investment project changes, and related financial data, which aligns with a Capital/Financing Update. It is not a full annual or interim report, nor an earnings release or audit report. It is a specialized report on fundraising usage, which fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive financial data, not just an announcement or certification, so it is not RPA or RNS.
2020-03-03 Chinese
第三届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the third meeting of the third board of directors of Betta Pharmaceuticals Co., Ltd. It includes voting results on various proposals related to a non-public stock issuance, authorization for the board to handle related matters, and other corporate governance issues. The document references the convening and conduct of the board meeting, voting outcomes, and mentions that these proposals will be submitted to the shareholders' meeting for approval. It also includes references to independent directors' opinions and other related announcements. The content is focused on board decisions and management-level approvals rather than financial results, audit opinions, or shareholder voting results at a general meeting. Therefore, the document fits best into the category of Board/Management Information (MANG), as it announces changes and decisions made by the board of directors and senior management.
2020-03-03 Chinese
独立董事关于第三届董事会第三次会议相关事项的独立意见
Audit Report / Information Classification · 95% confidence The document is an independent opinion report from the independent directors of Betta Pharmaceuticals Co., Ltd. regarding the company's third board meeting and specifically about a non-public issuance of A shares. It references compliance with Chinese securities laws, Shenzhen Stock Exchange rules, and includes detailed opinions on the issuance plan, feasibility, pricing, use of funds, and shareholder interests. The document is a formal independent directors' opinion on a financing proposal, not the financing announcement itself or a full financial report. It is not an earnings release, annual report, or management report. It is also not a regulatory filing or announcement of a report publication. The content aligns with an Audit Report / Information (AR) type, as it provides independent audit-like opinions on the legality, fairness, and feasibility of the financing plan and related disclosures, which is typical for standalone audit or independent director opinion reports related to financing activities. Q1 2020
2020-03-03 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.